Adaptimmune Therapeutics (ADAP) Competitors

Adaptimmune Therapeutics (NASDAQ:ADAP) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Do insiders and institutionals hold more shares of ADAP or GNFT?

31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 2.2% of GENFIT shares are held by institutional investors. 12.7% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 4.2% of GENFIT shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is ADAP or GNFT more profitable?

GENFIT has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -260.82%. GENFIT's return on equity of 0.00% beat Adaptimmune Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptimmune Therapeutics	-260.82%	-163.73%	-75.83%
GENFIT	N/A	N/A	N/A

Do analysts prefer ADAP or GNFT?

Adaptimmune Therapeutics currently has a consensus target price of $1.35, suggesting a potential upside of 1,989.13%. GENFIT has a consensus target price of $7.00, suggesting a potential upside of 63.36%. Given Adaptimmune Therapeutics' higher probable upside, equities analysts clearly believe Adaptimmune Therapeutics is more favorable than GENFIT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptimmune Therapeutics	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88
GENFIT	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more risk and volatility, ADAP or GNFT?

Adaptimmune Therapeutics has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.

Which has higher valuation and earnings, ADAP or GNFT?

GENFIT has lower revenue, but higher earnings than Adaptimmune Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptimmune Therapeutics	$178.03M	0.10	-$70.81M	-$0.65	-0.10
GENFIT	$76.77M	2.79	$1.63M	N/A	N/A

Does the media refer more to ADAP or GNFT?

In the previous week, Adaptimmune Therapeutics had 5 more articles in the media than GENFIT. MarketBeat recorded 7 mentions for Adaptimmune Therapeutics and 2 mentions for GENFIT. GENFIT's average media sentiment score of 0.67 beat Adaptimmune Therapeutics' score of 0.12 indicating that GENFIT is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptimmune Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GENFIT	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GENFIT beats Adaptimmune Therapeutics on 7 of the 13 factors compared between the two stocks.